Find RBN-2397 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Rbn-2397, 2381037-82-5, Atamparib [inn], Rbn2397, B1mw2me77a, 4-[[(2s)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1h-pyridazin-6-one
Molecular Formula
C20H23F6N7O3
Molecular Weight
523.4  g/mol
InChI Key
UQZCQKXJAXKZQH-LBPRGKRZSA-N
FDA UNII
B1MW2ME77A

RBN-2397
Atamparib is an orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration,atamparib selectively binds to PARP7 and restores interferon (type 1) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.
1 2D Structure

RBN-2397

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[(2S)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1H-pyridazin-6-one
2.1.2 InChI
InChI=1S/C20H23F6N7O3/c1-12(30-14-10-29-31-17(35)16(14)20(24,25)26)11-36-7-2-15(34)32-3-5-33(6-4-32)18-27-8-13(9-28-18)19(21,22)23/h8-10,12H,2-7,11H2,1H3,(H2,30,31,35)/t12-/m0/s1
2.1.3 InChI Key
UQZCQKXJAXKZQH-LBPRGKRZSA-N
2.1.4 Canonical SMILES
CC(COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
2.1.5 Isomeric SMILES
C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
B1MW2ME77A
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Rbn-2397

2. 2381037-82-5

3. Atamparib [inn]

4. Rbn2397

5. B1mw2me77a

6. 4-[[(2s)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1h-pyridazin-6-one

7. (s)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2h)-one

8. 3(2h)-pyridazinone, 5-(((1s)-1-methyl-2-(3-oxo-3-(4-(5-(trifluoromethyl)-2-pyrimidinyl)-1-piperazinyl)propoxy)ethyl)amino)-4-(trifluoromethyl)-

9. 5-(((2s)-1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2- Yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4- (trifluoromethyl)pyridazin-3(2h)-one

10. Atamparib [usan]

11. Unii-b1mw2me77a

12. Schembl21521281

13. Rbn-2397 [who-dd]

14. Bcp33764

15. Ex-a4038

16. Rbn2397;rbn 2397

17. Nsc825956

18. S8993

19. Who 11539

20. Nsc-825956

21. Ac-36483

22. As-76787

23. Hy-136174

24. Cs-0120272

25. D97647

26. A935907

2.4 Create Date
2020-06-01
3 Chemical and Physical Properties
Molecular Weight 523.4 g/mol
Molecular Formula C20H23F6N7O3
XLogP31.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count14
Rotatable Bond Count8
Exact Mass523.17665659 g/mol
Monoisotopic Mass523.17665659 g/mol
Topological Polar Surface Area112 Ų
Heavy Atom Count36
Formal Charge0
Complexity848
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2381037-82-5 / RBN-2397 API manufacturers, exporters & distributors?

RBN-2397 manufacturers, exporters & distributors 1

84

PharmaCompass offers a list of RBN-2397 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right RBN-2397 manufacturer or RBN-2397 supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred RBN-2397 manufacturer or RBN-2397 supplier.

PharmaCompass also assists you with knowing the RBN-2397 API Price utilized in the formulation of products. RBN-2397 API Price is not always fixed or binding as the RBN-2397 Price is obtained through a variety of data sources. The RBN-2397 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

RBN-2397

Synonyms

2381037-82-5, Atamparib [inn], Rbn2397, B1mw2me77a, 4-[[(2s)-1-[3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy]propan-2-yl]amino]-5-(trifluoromethyl)-1h-pyridazin-6-one, (s)-5-((1-(3-oxo-3-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2h)-one

Cas Number

2381037-82-5

Unique Ingredient Identifier (UNII)

B1MW2ME77A

About RBN-2397

Atamparib is an orally available small molecule inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 7, with potential immunomodulating and antineoplastic activities. Upon oral administration,atamparib selectively binds to PARP7 and restores interferon (type 1) signaling. This may lead to the induction of both innate and adaptive immune responses, and the inhibition of tumor growth and proliferation. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.

RBN-2397 Manufacturers

A RBN-2397 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RBN-2397, including repackagers and relabelers. The FDA regulates RBN-2397 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RBN-2397 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

RBN-2397 Suppliers

A RBN-2397 supplier is an individual or a company that provides RBN-2397 active pharmaceutical ingredient (API) or RBN-2397 finished formulations upon request. The RBN-2397 suppliers may include RBN-2397 API manufacturers, exporters, distributors and traders.

RBN-2397 GMP

RBN-2397 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of RBN-2397 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RBN-2397 GMP manufacturer or RBN-2397 GMP API supplier for your needs.

RBN-2397 CoA

A RBN-2397 CoA (Certificate of Analysis) is a formal document that attests to RBN-2397's compliance with RBN-2397 specifications and serves as a tool for batch-level quality control.

RBN-2397 CoA mostly includes findings from lab analyses of a specific batch. For each RBN-2397 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

RBN-2397 may be tested according to a variety of international standards, such as European Pharmacopoeia (RBN-2397 EP), RBN-2397 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RBN-2397 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty